Company Performance Metrics
V5med was established in 2023 with a primary focus on Medical Image AI. Leveraging cutting-edge AI technology, V5med collaboratively partnered with prestigious institutions such as Taipei Veterans General Hospital, National Taiwan University Hospital, and the Taiwan Lung Cancer Society. Together, they spearheaded the development of V5 Lung AI, an
advanced lung cancer screening computer-aided detection (CAD) system.
V5 Lung AI revolutionizes medical practice by enabling physicians to accurately detect nodules on LDCT images, significantly reducing examination times. Beyond its efficiency, V5 Lung AI promptly annotates nodules and furnishes crucial information about their characteristics, including diameter, volume, nodule type, and lung-RADS score. Notably, the technology autonomously conducts comparative analyses of nodule growth across different scan times, providing instant volume doubling time (VDT) assessments. Furthermore, V5 Lung AI generates comprehensive reports following AI analysis, aligning with ACR Lung-RADS and Fleischner guidelines.
In addition to its pioneering Lung AI capabilities, V5med remains dedicated to advancing lung cancer cytology analysis, COPD diagnostics, coronary artery calcification assessments, and AI conductor platforms. The ultimate aspiration is to solidify V5med's position as a global frontrunner in the field of image AI solutions.
